LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates. - Dataset (ID:20251)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Mean Relative Cell Count | Standard Error of the Mean for Relative Cell Count | Mean Normalized Growth Rate Inhibition Value | Standard Error of the Mean for Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | NVP-TAE684 | 0.37 | uM | LJP6 | 0.9504 | 0.0264 | 0.9282 | 0.0401 |
| SK-BR-3 | NVP-TAE684 | 1.11 | uM | LJP6 | 0.8031 | 0.0569 | 0.6911 | 0.0910 |
| SK-BR-3 | NVP-TAE684 | 3.33 | uM | LJP6 | 0.5164 | 0.0478 | 0.1967 | 0.1160 |
| SK-BR-3 | NVP-TAE684 | 10 | uM | LJP6 | 0.2886 | 0.0539 | -0.2321 | 0.0394 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 1.0595 | 0.0322 | 1.0842 | 0.0469 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 0.2596 | 0.0035 | -0.2880 | 0.0785 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP5 | 0.6934 | 0.0835 | 0.5296 | 0.1325 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP6 | 0.2496 | 0.0032 | -0.3091 | 0.0716 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP5 | 0.3029 | 0.0398 | -0.1702 | 0.1288 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP6 | 0.2615 | 0.0071 | -0.2836 | 0.0835 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 0.2719 | 0.0300 | -0.2328 | 0.1176 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 0.2425 | 0.0150 | -0.3237 | 0.0783 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 0.2434 | 0.0233 | -0.2904 | 0.1044 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 0.2076 | 0.0129 | -0.3984 | 0.0787 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP5 | 0.2189 | 0.0201 | -0.3435 | 0.1065 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP6 | 0.1685 | 0.0189 | -0.4855 | 0.0978 |
| SK-BR-3 | PD173074 | 0.04 | uM | LJP6 | 1.0937 | 0.0449 | 1.1395 | 0.0677 |
| SK-BR-3 | PD173074 | 0.12 | uM | LJP6 | 1.0777 | 0.0507 | 1.1201 | 0.0762 |
| SK-BR-3 | PD173074 | 0.37 | uM | LJP6 | 1.0550 | 0.0312 | 1.0845 | 0.0490 |
| SK-BR-3 | PD173074 | 1.11 | uM | LJP6 | 1.0897 | 0.0434 | 1.1326 | 0.0664 |
| SK-BR-3 | PD173074 | 3.33 | uM | LJP6 | 1.0779 | 0.0413 | 1.1196 | 0.0641 |
| SK-BR-3 | PD173074 | 10 | uM | LJP6 | 0.5232 | 0.0280 | 0.2094 | 0.1129 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 0.7995 | 0.0399 | 0.6865 | 0.0813 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 0.8766 | 0.0290 | 0.8079 | 0.0553 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 0.8414 | 0.0528 | 0.7529 | 0.0869 |